Palvella Therapeutics (PVLA) Accumulated Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Accumulated Expenses data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 35.06% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 35.06% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, down 65.02% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.5 million, up from $1.9 million in the prior quarter.
• Over the last five years, Accumulated Expenses for PVLA reached as high as $14.1 million in Q1 2022 and fell as low as $175000.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $6.0 million across 5 years, with a median of $3.5 million in 2026.
• Across the five-year window, Accumulated Expenses slumped 98.37% in 2023 and surged 3028.0% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $10.7 million in 2022, then slumped by 98.37% to $175000.0 in 2023, then jumped by 3028.0% to $5.5 million in 2024, then slumped by 65.02% to $1.9 million in 2025, then jumped by 80.84% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $3.5 million in Q1 2026, $1.9 million in Q4 2025, and $1.2 million in Q3 2025.